Freedom Capital upgraded shares of Niagen Bioscience (NASDAQ:NAGE – Free Report) to a strong-buy rating in a research report report published on Monday morning,Zacks.com reports.
Several other equities research analysts have also issued reports on the stock. Wall Street Zen lowered shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a research note on Tuesday, April 21st. Canaccord Genuity Group decreased their price objective on Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, July 1st. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $10.50.
Get Our Latest Research Report on NAGE
Niagen Bioscience Stock Down 2.3%
Niagen Bioscience (NASDAQ:NAGE – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. Niagen Bioscience had a net margin of 14.29% and a return on equity of 22.68%. The business had revenue of $31.47 million for the quarter. On average, sell-side analysts anticipate that Niagen Bioscience will post 0.22 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Niagen Bioscience
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NAGE. New York State Teachers Retirement System acquired a new position in shares of Niagen Bioscience in the fourth quarter valued at $30,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Niagen Bioscience during the 3rd quarter worth about $45,000. Quantbot Technologies LP acquired a new stake in shares of Niagen Bioscience during the 3rd quarter worth about $48,000. Kestra Advisory Services LLC bought a new stake in shares of Niagen Bioscience during the 4th quarter worth about $70,000. Finally, SummitTX Capital L.P. bought a new stake in shares of Niagen Bioscience during the 4th quarter worth about $79,000. 15.41% of the stock is owned by institutional investors.
About Niagen Bioscience
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.
Further Reading
- Five stocks we like better than Niagen Bioscience
- Sony Is Going All-Digital—But Investors Should Watch This Instead
- Scotiabank Sees a New Growth Story for Cloudflare
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
